11/25
01:48 pm
brtx
Biorestorative Therapies (NASDAQ:BRTX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biorestorative Therapies (NASDAQ:BRTX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
07:00 am
brtx
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
Medium
Report
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
11/12
06:52 pm
brtx
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:05 pm
brtx
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
11/5
04:30 pm
brtx
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Medium
Report
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
10/27
07:30 am
brtx
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Medium
Report
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
10/22
09:35 am
brtx
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
Low
Report
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio